大型综合癌症中心网络中乳腺癌临床路径变更对淋巴结放疗标准化的影响
该研究评估了乳腺癌临床路径(CP)变更对腋窝前哨淋巴结阳性(+SLN)但未行腋窝淋巴结清扫患者术后放疗野选择的影响。CP推荐微转移(pN1mi)采用改良切线野(MT)包括I/II水平淋巴结,宏转移(pN1a)伴不良因素时采用MT包括I/II水平及第三锁骨上淋巴结(SCN)±内乳淋巴结。变更后全乳放疗单独使用减少,MT及MT+SCN使用增加,且与CP变更相关。
要点
- CP变更后,pN1mi和pN1a患者全乳放疗单独使用比例分别降至5%(总体),MT使用率达58%。
- MT使用与CP变更相关,第三SCN野使用与CP变更、pN分期、包膜外侵犯及不良因素总数相关。
- CP能将证据转化为管理计划,提高与质量指南的一致性和依从性。
核心结论
- 临床路径变更与乳腺癌+SLN患者术后放疗野标准化相关,减少了不必要的实践差异。
研究设计与样本
- 回顾性研究,纳入233例接受保乳手术的+SLN但未行腋窝淋巴结清扫的乳腺癌患者。
主要发现
- CP变更前127例中,pN1mi患者35%和pN1a患者22%接受全乳放疗单独治疗。
- CP变更后106例中,5%接受全乳放疗单独,58%接受MT,38%接受MT+SCN野。
- MT使用与CP变更相关,第三SCN野使用与CP变更、pN分期、包膜外侵犯及不良因素总数相关。
关键数值与推荐
- CP推荐pN1mi患者采用MT包括I/II水平淋巴结。
- CP推荐pN1a伴不良因素患者采用MT包括I/II水平淋巴结及第三SCN淋巴结±内乳淋巴结。
临床怎么用
- 对于+SLN但未行腋窝淋巴结清扫的保乳术后患者,可参考CP推荐选择MT或MT+SCN野以提高放疗野一致性。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies demonstrate safety of omitting axillary nodal dissection for early-stage breast cancer with positive sentinel lymph node (+SLN) biopsy, although trial designs differed in radiation therapy (RT) fields. Regional nodal irradiation was separately shown to improve outcomes in high-risk patients. This led to lack of consensus in RT volumes. Clinical pathways (CPs) standardize care where practice varies unnecessarily. We evaluated the impact of changes to a CP guiding postoperative RT in women with +SLNs on practice patterns throughout a network. METHODS AND MATERIALS: We implemented a CP for management of breast cancer with postoperative RT designed to promote uniform nodal treatment. The CP recommended modified tangents (MTs) including level I/II nodes for women with micrometastases (pN1mi). For women with macrometastases (pN1a), CPs recommended including level I/II LN in MT and a third supraclavicular node (SCN) LN ± internal mammary nodes for women with adverse factors present. RESULTS: RT fields of 233 women undergoing breast-conserving surgery with +SLN but not axillary nodal dissection were retrospectively reviewed: 25% had pN1mi disease and 75% pN1a. Of 127 women treated before CP changes, 35% with pN1mi and 22% with pN1a were treated with whole-breast irradiation alone. Following CP changes, 106 women were treated: 5% with whole-breast irradiation alone, 58% with MT, and 38% with MT + SCN field. Utilization of MT was associated with CP changes. Utilization of a third SCN field was associated with CP changes, pN stage, extracapsular extension, and total number of adverse factors. CONCLUSIONS: CPs translate published data and institutional experience into management plans that promote evidence-based care and eliminate unnecessary practice variations. Recognizing that postoperative RT treatment volumes were heterogeneous, we modified the CP based upon the latest evidence for regional nodal irradiation, after which we found increased compliance and consistency with quality guidelines, which will also aid in tracking outcomes in future investigations.
引用
- Gebhardt BJ, Thomas J, Horne ZD, et al. Standardization of nodal radiation therapy through changes to a breast cancer clinical pathway throughout a large, integrated cancer center network. Pract Radiat Oncol. 2017. PMID: 28939351. doi:10.1016/j.prro.2017.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。